Oragenics,
Inc. (NYSE MKT:OGEN) (the “Company”) today announced that in view of
the unusual market activity in the Company’s stock, the NYSE MKT (the
“Exchange”) has contacted the Company in accordance with its usual
practice. The Company stated that its policy is not to comment on
unusual market activity.
About Oragenics, Inc.
Oragenics, Inc. is focused on becoming the world leader in novel
antibiotics against infectious disease and probiotics for oral health in
humans and pets. Oragenics, Inc. has established two exclusive worldwide
channel collaborations with Intrexon Corporation Inc., a synthetic
biology company. The collaborations will allow Oragenics access to
Intrexon's proprietary technologies with the idea of accelerating the
development of much needed new antibiotics that will work against
resistant strains of bacteria and new therapeutic probiotics designed to
alleviate symptoms from oral diseases. Oragenics also develops, markets
and sells proprietary OTC probiotics specifically designed to enhance
oral health for humans and pets, under the brand names Evora
and ProBiora
in more than 13 countries worldwide.
For more information about Oragenics, visit www.oragenics.com.
Follow Oragenics on Facebook
and Twitter.
Safe Harbor Statement: Under the Private Securities
Litigation Reform Act of 1995: This release includes forward-looking
statements that reflect management’s current views with respect to
future events and performance. These forward-looking statements are
based on management’s beliefs and assumptions and information currently
available. The words “believe,” “expect,” “anticipate,” “intend,”
“estimate,” “project” and similar expressions that do not relate solely
to historical matters identify forward-looking statements. Investors
should be cautious in relying on forward-looking statements because they
are subject to a variety of risks, uncertainties, and other factors that
could cause actual results to differ materially from those expressed in
any such forward-looking statements. These factors include, but are not
limited to those described in the filings of Intrexon and Oragenics with
the U.S. Securities and Exchange Commission. Any responsibility to
update forward-looking statements is expressly disclaimed.
Copyright Business Wire 2014